A pharmaceutical composition for treating eczema and its preparation method and application
By combining oil tea with medicinal materials such as saponin, somatosus, honeysuckle, corundum, and coptis chinensis, and using microbial fermentation and extraction method to prepare pharmaceutical compositions, the problems of many types of raw materials, high costs and poor treatment effects in eczema treatment are solved. The effect of fundamentally improving eczema symptoms and reducing recurrence rates is achieved.
Patent Information
- Application Number
- CN202310567824.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-19
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-05-19
AI Technical Summary
The existing eczema treatment drug formula has many types of raw materials, high cost, poor treatment effect, high recurrence rate, inconvenient traditional decoction process, and has failed to fundamentally solve the causes of eczema.
Using oleifera as the main medicinal component, combined with medicinal materials such as saponin, somatosus, honeysuckle, cypress, and coptis chinensis, to prepare pharmaceutical compositions through microbial fermentation and extraction. The fermentation broth has antibacterial and anti-inflammatory effects and is used to target the causes of eczema. Coordinated treatment.
Significantly improves eczema symptoms, reduces the levels of immunoglobulin IgE and interleukin IL-4 and IL-17, reduces eczema recurrence, provides a variety of dosage form options, is safe and non-toxic, and is suitable for industrial production.
Smart Images

Figure GHA0000007232510000101 
Figure GHA0000007232510000111 
Figure GHA0000007232510000112
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical inventions, and in particular relates to a pharmaceutical composition for treating eczema, and a preparation method and application thereof. Background Art
[0002] Eczema is a recurrent inflammation of the superficial dermis and epidermis. The lesions are symmetrically distributed, the disease is protracted, and the skin lesions are dark red or brownish red macules or papules, which are lichenified, accompanied by severe itching, often aggravated at night, with a long course and easy to recur. In the acute phase, red maculopapular rashes, even erosions, exudates, and crusts can be seen on the skin; in the chronic phase, the skin is dry and desquamated, lichenified, accompanied by severe itching, and is prone to occur in the folds of the limbs, neck, etc. Whether it is a skin disease infected by pathogens or a skin disease caused by eczema, it will cause symptoms such as itching, redness, swelling, and pain in patients, and its pathogenesis is complex. In clinical practice, topical glucocorticoids are often used, supplemented by symptomatic treatments such as antihistamines and antibacterials. The efficacy is limited, the side effects are large, and the recurrence rate after discontinuation of the drug is high.
[0003] As a natural medicine, Chinese medicine is rich in a variety of effective ingredients. Compared with Western medicine, it has the advantages of multiple components and multiple targets, safety and non-toxicity, and fewer side effects in the treatment of diseases. Therefore, finding methods from traditional Chinese medicine is one of the effective ways to treat eczema, which has attracted widespread attention from researchers. At present, the Chinese patent medicines used to treat eczema on the market are mainly topical and oral medicines. For topical medicines, there are dehumidifying and itching cream, paeonol ointment, centipede ointment, Shennong Baicao ointment, and baby lithospermum officinale cream; for oral medicines, there are moistening and itching capsules, Xiaofeng and itching granules, Jinchan itching capsules, Baixuan Xiatare tablets, silver capsules, compound glycyrrhizic acid tablets, etc. Existing drugs have many types of raw materials and high production costs; the scope of clinical drug treatment is mostly single, and multiple ointments are often required for combined treatment, which is troublesome to use; it is easy to relapse after treatment, and the treatment effect is poor.
[0004] Application number CN201410018822.2, invention name "A medicine for treating eczema", discloses an important formula for treating eczema, which is composed of 11 medicinal materials including Rehmannia root, yam, lily, honeysuckle, dandelion, Schisandra chinensis, Poria cocos, Atractylodes macrocephala, Angelica sinensis, Amomum villosum and mint. The formula is taken orally and applied externally to treat eczema, and has quick effect, good efficacy and high cure rate.
[0005] Application number CN201610385430.9, the invention name is a kind of eczema powder for infants and its preparation method, which discloses a Chinese medicine composition for treating eczema and its preparation method, the prescription contains raw rhubarb, coptis root, phellodendron, sophora flavescens, xanthium sibiricum, alum, dragon bone and flower fragrance powder. Its preparation process is to take each raw medicinal material for preparation; extract honeysuckle and peony flower by ultrasonic twice, filter, collect the filtrate, reduce pressure and concentrate, dry and grind to obtain flower fragrance powder for standby use; mix the remaining medicinal materials and then perform ultrafine grinding, add to the flower fragrance powder, grind evenly, and obtain. The prescription is an external powder, with direct efficacy, no toxic side effects, and easy for children to accept.
[0006] Application number CN201510005126.2, the invention name is a Chinese medicine composition for treating eczema, which discloses a prescription for external use of medicine for treating eczema, which is composed of 15 medicinal materials, including borneol, honeysuckle, sophora flavescens, indigo, talcum powder, calamine, alum, evodia rutaecarpa, cnidium monnieri, rhubarb, phellodendron, maple ball, coptis root, capillaris, and zanthoxylum bungeanum. The prescription is prepared by mixing and decocting the raw materials according to the traditional decoction process, and then applying it to the surface of the affected area, which can reduce the itching of the skin and mainly has a soothing effect.
[0007] The technical problems existing in the above patents are: 1) The formula contains many raw medicinal materials, and precious medicinal materials such as dragon bones are used, which is costly and not conducive to industrial production; 2) Although the symptoms can be relieved after use, the recurrence rate is high and the cause of the disease is not fundamentally solved; 3) The traditional decoction process is used, which is inconvenient to carry and has limited use; 4) The treatment time is long and the effect is not good.
[0008] To solve the above problems, the research team of the present invention noticed that camellia oleifera contains a variety of chemical components that exert medicinal effects, such as triterpenes and triterpenoid saponins, flavonoids, fatty acids, polyphenols, polysaccharides and other chemical components. Studies have shown that camellia oleifera has good effects in antibacterial, anti-inflammatory, heat-clearing and detoxifying, and has great research and development value in the field of medicine. At present, there is no document publicly available on the technical solution of directly applying camellia oleifera to treat eczema.
[0009] The research team of the present invention has developed a medicinal composition and its compound preparation for treating eczema based on the pathogenesis of eczema and the medicinal efficacy of camellia oleifera, combined with the compatibility principle of traditional Chinese medicine, after scientific compatibility and process research. By giving play to the synergistic effect between various raw materials, the cause of eczema is fundamentally solved, and the medicinal composition has the effect of promoting the increase of immunoglobulin IgE and immune cell CD4+ in the serum of eczema C57 mice, and has the effect of down-regulating interleukin IL-4 and IL-17, which can significantly improve the eczema symptoms of eczema C57 mice. The present invention adopts preparation processes such as microbial fermentation extraction method, and the fermentation liquid also has an antibacterial effect on Staphylococcus aureus, which is beneficial to the treatment of eczema. Summary of the invention
[0010] The object of the present invention is to provide a pharmaceutical composition for treating eczema.
[0011] Another object of the present invention is to provide a method for preparing a pharmaceutical composition for treating eczema.
[0012] Another object of the present invention is to provide a pharmaceutical composition for use in treating skin diseases such as acute, chronic and pediatric eczema caused by the environment, pathogens and immune disorders.
[0013] The invention provides a pharmaceutical composition for treating eczema, which is prepared from the following raw materials in parts by weight: 10-20 parts of camellia oleifera seed, 10-20 parts of saponin, 6-15 parts of sophora flavescens, 5-12 parts of honeysuckle, 3-10 parts of phellodendron amurense, and 1-7 parts of coptis chinensis.
[0014] Preferably, the pharmaceutical composition is made of the following raw materials in parts by weight: 14-16 parts of camellia oleifera seed, 14-16 parts of sapodilla fruit, 8-12 parts of sophora flavescens, 7-9 parts of honeysuckle, 5-7 parts of phellodendron amurense, and 3-5 parts of coptis root.
[0015] More preferably, the pharmaceutical composition is made of the following raw materials in parts by weight: 15 parts of camellia oleifera, 15 parts of sapodilla fruit, 10 parts of sophora flavescens, 8 parts of honeysuckle, 6 parts of phellodendron amurense, and 4 parts of coptis chinensis.
[0016] The present invention provides a method for preparing a pharmaceutical composition for treating eczema, the method comprising the following steps:
[0017] 1) Crush the six medicinal materials of camellia oleifera, Gleditsia sinensis, Sophora flavescens, Flos Lonicerae, Phellodendron amurense, and Rhizoma Coptidis separately, and pass through a 10-30 mesh sieve to obtain powder;
[0018] 2) Add 10 to 25 times the amount of purified water to the oil-tea camellia oleifera powder, heat to boil, and then simmer for 25 to 35 minutes to mature it;
[0019] 3) adding the powders of Chinese sapodilla, sophora flavescens, honeysuckle, phellodendron and coptis chinensis to the stale camellia oleifera seed after being matured in step 2), deducting the volume of the water content of the camellia oleifera seed, adding 10 to 20 times the amount of purified water and 10% to 20% by weight of white sugar of the total amount of the camellia oleifera seed, heating and boiling for sterilization, cooling to room temperature, adding 8 to 10% of high-efficiency distiller's yeast for fermentation and extraction for 18 to 22 days, inactivating at high temperature, filtering the fermented liquid, and concentrating the supernatant to 1 / 3 of the volume of the original liquid to obtain a concentrated liquid;
[0020] 4) Adding pharmaceutically acceptable excipients to the concentrated solution to prepare a pharmaceutically acceptable preparation.
[0021] Preferably, the method comprises the following steps:
[0022] A1: Crush the six medicinal materials of camellia oleifera, Gleditsia sinensis, Sophora flavescens, Flos lonicerae, Phellodendron chinense, and Rhizoma Coptidis respectively, and pass through a 20-mesh sieve to obtain powder;
[0023] A2: Add 20 times the amount of purified water to the oil-tea camellia herb powder, heat to boil, and then simmer for 30 minutes to mature it;
[0024] A3: Add the powder of Chinese ginseng, sophora flavescens, honeysuckle, phellodendron and coptis chinensis to the matured camellia oleifera dregs in step 2), deduct the volume of the water content of the camellia oleifera dregs, add 15 times the amount of purified water and 15% by weight of white sugar to the total amount of the medicinal materials, heat and boil to sterilize, cool to room temperature, add 9% high-efficiency distiller's yeast and ferment for 20 days, inactivate at high temperature, filter the fermentation liquid, take the supernatant and concentrate to 1 / 3 of the volume of the original liquid to obtain a concentrated liquid;
[0025] A4: Add pharmaceutically acceptable excipients to the concentrate to prepare a pharmaceutically acceptable preparation.
[0026] More preferably, in step 3) of the above preparation method, after adding high-efficiency distiller's yeast for fermentation for 5 to 6 days, 0.5% to 1% of acetobacter may be added to continue fermentation.
[0027] The preparation of the present invention is a semisolid preparation or a liquid preparation.
[0028] The semisolid preparation of the present invention is an ointment, and the liquid preparation is a nano-microemulsion, a liniment, a gel, or an aerosol.
[0029] The gelling agent of the present invention is a nano hydrogel.
[0030] The preparation method of the nano hydrogel of the present invention is:
[0031] B1: Take a certain amount of chitosan and sodium tripolyphosphate, add chitosan to 2% to 4% acetic acid solution, add sodium tripolyphosphate to distilled water, stir and dissolve completely, and prepare chitosan acetic acid solution with a concentration of 2 mg / ml and sodium tripolyphosphate aqueous solution with a concentration of 1.25 mg / ml respectively;
[0032] B2: Take 25 ml of the formula concentrated solution prepared in step A3 and add it to the chitosan acetate solution prepared in step B1. Then mix the chitosan acetate solution containing the formula concentrated solution with 10 ml of the sodium tripolyphosphate aqueous solution prepared in step B1, and stir and mix them evenly to cross-link them to obtain a nano hydrogel.
[0033] The pharmaceutical composition of the present invention is used in treating acute, chronic and pediatric eczema caused by the environment, pathogens and immune disorders.
[0034] The beneficial effects of the present invention are as follows:
[0035] 1. The present invention obtains a pharmaceutical composition for treating eczema through formula screening. Pharmacodynamic experiments have confirmed that the pharmaceutical composition has the effects of antibacterial and anti-inflammatory, clearing away heat and detoxifying, and has a good therapeutic effect on eczema.
[0036] 2. The present invention follows the folk medicine habits of using medicinal materials, combines the compatibility principles of traditional Chinese medicine, and has reasonable compatibility. The medicinal materials used are all non-toxic and side-effect. The acute toxicity test shows that no mouse death was observed when mice were given 0.7mL / 20g of the spray of the present invention by gavage (equivalent to 1230 times the human dosage).
[0037] 3. The pharmacodynamic experimental results of the present invention show that, after continuous administration of the fermentation broth of the present invention, with or without acetic acid, to C57 mice with an eczema model for 21 days, the proliferation of immunoglobulin IgE and immune cells CD4+ in the serum of C57 mice with eczema was promoted, and interleukins IL-4 and IL-17 were downregulated, and the C57 mice with eczema were basically cured.
[0038] 4. The antibacterial experiment of the present invention shows that the drug formulation of the present invention has a very obvious effect on acute eczema and skin diseases infected by Staphylococcus aureus, and has a good curative effect on skin diseases such as chronic eczema and pediatric eczema.
[0039] 5. The pharmaceutical composition of the present invention is a pure Chinese medicine formula, which is safe and has no toxic side effects, thus ensuring the safety of medication. Among them, the oil tea dregs are the residues left after tea seeds are fried for oil, thus realizing the recycling of the residues and giving full play to the medicinal value of Chinese medicinal materials. The raw material cost is low and it is suitable for industrial production.
[0040] 6. The preparation process of the present invention is prepared by fermenting several medicinal materials, so that the effective ingredients of the medicinal materials are fully extracted, thereby ensuring the effectiveness of the medicine.
[0041] 7. The present invention can be made into a variety of dosage forms, including nano-microemulsions, gels, ointments, aerosols or sprays. In particular, the prepared nano-hydrogel preparations are stable and easy to absorb, and have obvious effects on acute and chronic eczema skin diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 The skin changes of C57 mice 28 days after using the formulation of the present invention;
[0043] Figure 2 The formula of the present invention is used to treat the pathological changes of eczema skin lesions on the back of C57 mice with eczema (HE200×);
[0044] Figure 3The present invention shows the inhibitory effect of the acetic acid bacteria fermentation liquid on Staphylococcus aureus and Escherichia coli. DETAILED DESCRIPTION
[0045] The present invention is further described below by means of specific examples, but is not intended to limit the protection scope of the present invention.
[0046] Embodiment 1:
[0047] Prescription: 15 parts of camellia oleifera, 15 parts of gleditsia sinensis, 10 parts of sophora flavescens, 8 parts of honeysuckle, 6 parts of phellodendron chinense, and 4 parts of coptis chinensis.
[0048] Embodiment 2:
[0049] Prescription: 10 parts of camellia oleifera, 10 parts of sapodilla, 6 parts of sophora flavescens, 5 parts of honeysuckle, 3 parts of phellodendron, and 1 part of coptis root.
[0050] Embodiment 3:
[0051] Prescription: 12 parts of camellia oleifera, 12 parts of sapodilla, 7 parts of sophora flavescens, 6 parts of honeysuckle, 4 parts of phellodendron, and 2 parts of coptis root.
[0052] Embodiment 4:
[0053] Prescription: 14 parts of camellia oleifera, 14 parts of Gleditsia sinensis, 8 parts of Sophora flavescens, 7 parts of Honeysuckle, 5 parts of Phellodendron chinense, and 3 parts of Coptis chinensis.
[0054] Embodiment 5:
[0055] Prescription: 16 parts of camellia oleifera, 16 parts of gleditsia sinensis, 12 parts of sophora flavescens, 9 parts of honeysuckle, 7 parts of phellodendron chinense, and 5 parts of coptis chinensis.
[0056] Embodiment 6:
[0057] Prescription: 18 parts of camellia oleifera, 18 parts of gleditsia sinensis, 14 parts of sophora flavescens, 11 parts of honeysuckle, 8 parts of phellodendron chinense, and 6 parts of coptis chinensis.
[0058] Embodiment 7:
[0059] Prescription: 20 parts of camellia oleifera, 20 parts of gleditsia sinensis, 15 parts of sophora flavescens, 12 parts of honeysuckle, 10 parts of phellodendron chinense, and 7 parts of coptis chinensis.
[0060] Any one of the formulas of Examples 1-7 is prepared according to any one of the preparation methods of Examples 8-15:
[0061] Embodiment 8:
[0062] Preparation method:
[0063] (1) Crush the six medicinal materials of camellia oleifera, Gleditsia sinensis, Sophora flavescens, Flos lonicerae, Phellodendron chinense, and Rhizoma Coptidis respectively, and pass through a 20-mesh sieve to obtain powder;
[0064] (2) Add 20 times the amount of purified water to the oil-tea camellia oleifera powder, heat to boil, and then simmer for 30 minutes to mature it;
[0065] (3) adding the powders of Chinese sapodilla, sophora flavescens, honeysuckle, phellodendron amurense and coptis chinensis to the matured camellia oleifera seed cake in step 2), deducting the volume of the water content of the camellia oleifera seed cake, adding 15 times the amount of purified water and 15% by weight of white sugar to the total amount of the camellia oleifera seed cake, heating and boiling for sterilization, cooling to room temperature, adding 9% high-efficiency distiller's yeast for fermentation and extraction for 20 days, inactivating the mixture at high temperature, filtering the fermentation liquid, and concentrating the supernatant to 1 / 3 of the volume of the original liquid to obtain a concentrated liquid;
[0066] (4) taking a certain amount of chitosan and sodium tripolyphosphate, adding chitosan to a 2% acetic acid solution, and adding sodium tripolyphosphate to distilled water, stirring and dissolving them completely to obtain a chitosan acetic acid solution with a concentration of 2 mg / ml and a sodium tripolyphosphate aqueous solution with a concentration of 1.25 mg / ml, respectively;
[0067] (5) Take 25 ml of the concentrated solution prepared in step (3) and add it to the chitosan acetate solution prepared in step (4), then mix the chitosan acetate solution containing the concentrated solution with 10 ml of the sodium tripolyphosphate aqueous solution prepared in step (4), and stir and mix them to achieve cross-linking, so as to obtain a nano hydrogel.
[0068] Embodiment 9:
[0069] Preparation method:
[0070] (1) Crush the six medicinal materials of camellia oleifera, Gleditsia sinensis, Sophora flavescens, Flos lonicerae, Phellodendron chinense, and Rhizoma Coptidis respectively, and pass through a 10-mesh sieve to obtain powder;
[0071] (2) Add 10 times the amount of purified water to the oil-tea camellia herb powder, heat to boil, and then simmer for 25 minutes to mature it;
[0072] (3) adding the powders of Chinese sapodilla, sophora flavescens, honeysuckle, phellodendron amurense and coptis chinensis to the matured camellia oleifera seed cake in step 2), deducting the volume of the water content of the camellia oleifera seed cake, adding 10 times the amount of purified water and 10% by weight of white sugar to the total amount of the camellia oleifera seed cake, heating and boiling for sterilization, cooling to room temperature, adding 8% high-efficiency distiller's yeast for fermentation and extraction for 18 days, inactivating the mixture at high temperature, filtering the fermentation liquid, and concentrating the supernatant to 1 / 3 of the volume of the original liquid to obtain a concentrated liquid;
[0073] (4) taking a certain amount of chitosan and sodium tripolyphosphate, adding chitosan to a 3% acetic acid solution, and adding sodium tripolyphosphate to distilled water, stirring and dissolving them completely to obtain a chitosan acetic acid solution with a concentration of 2 mg / ml and a sodium tripolyphosphate aqueous solution with a concentration of 1.25 mg / ml, respectively;
[0074] (5) Take 25 ml of the concentrated solution prepared in step (3) and add it to the chitosan acetate solution prepared in step (4), then mix the chitosan acetate solution containing the concentrated solution with 10 ml of the sodium tripolyphosphate aqueous solution prepared in step (4), and stir and mix them to achieve cross-linking, so as to obtain a nano hydrogel.
[0075] Embodiment 10:
[0076] Preparation method:
[0077] (1) Crush the six medicinal materials of camellia oleifera, Gleditsia sinensis, Sophora flavescens, Flos lonicerae, Phellodendron chinense, and Rhizoma Coptidis respectively, and pass through a 30-mesh sieve to obtain powder;
[0078] (2) Add 25 times the amount of purified water to the oil-tea camellia herb powder, heat to boil, and then simmer for 35 minutes to mature it;
[0079] (3) adding the powders of Chinese sapodilla, sophora flavescens, honeysuckle, phellodendron amurense and coptis chinensis to the matured camellia oleifera seed cake in step 2), deducting the volume of the water content of the camellia oleifera seed cake, adding 20 times the amount of purified water and 20% by weight of white sugar to the total amount of the camellia oleifera seed cake, heating and boiling for sterilization, cooling to room temperature, adding 10% of high-efficiency distiller's yeast for fermentation and extraction for 22 days, inactivating the mixture at high temperature, filtering the fermentation liquid, and concentrating the supernatant to 1 / 3 of the volume of the original liquid to obtain a concentrated liquid;
[0080] (4) taking a certain amount of chitosan and sodium tripolyphosphate, adding chitosan to a 4% acetic acid solution, and adding sodium tripolyphosphate to distilled water, stirring and dissolving them completely to obtain a chitosan acetic acid solution with a concentration of 2 mg / ml and a sodium tripolyphosphate aqueous solution with a concentration of 1.25 mg / ml, respectively;
[0081] (5) Take 25 ml of the concentrated solution prepared in step (3) and add it to the chitosan acetate solution prepared in step (4), then mix the chitosan acetate solution containing the concentrated solution with 10 ml of the sodium tripolyphosphate aqueous solution prepared in step (4), and stir and mix them to achieve cross-linking, so as to obtain a nano hydrogel.
[0082] Embodiment 11:
[0083] Preparation method:
[0084] (1) Crush the six medicinal materials of camellia oleifera, Gleditsia sinensis, Sophora flavescens, Flos lonicerae, Phellodendron chinense, and Rhizoma Coptidis respectively, and pass through a 20-mesh sieve to obtain powder;
[0085] (2) Add 20 times the amount of purified water to the oil-tea camellia oleifera powder, heat to boil, and then simmer for 30 minutes to mature it;
[0086] (3) adding the powders of Chinese sapodilla, sophora flavescens, honeysuckle, phellodendron amurense and coptis chinensis to the oil tea dregs matured in step 2), deducting the volume of the water content of the oil tea dregs, adding 15 times the amount of purified water of the total amount of the medicinal materials and 15% by weight of white sugar of the total amount of the medicinal materials, heating and boiling for sterilization, cooling to room temperature, adding 9% of high-efficiency distiller's yeast and fermenting for 6 days, adding 0.5% to 1% of acetobacter and continuing to ferment and extract for 20 days, inactivating at high temperature, filtering the fermentation liquid, and concentrating the supernatant to 1 / 3 of the volume of the original liquid to obtain a concentrated liquid;
[0087] (4) taking a certain amount of chitosan and sodium tripolyphosphate, adding chitosan to a 2% acetic acid solution, and adding sodium tripolyphosphate to distilled water, stirring and dissolving them completely to obtain a chitosan acetic acid solution with a concentration of 2 mg / ml and a sodium tripolyphosphate aqueous solution with a concentration of 1.25 mg / ml, respectively;
[0088] (5) Take 25 ml of the concentrated solution prepared in step (3) and add it to the chitosan acetate solution prepared in step (4), then mix the chitosan acetate solution containing the concentrated solution with 10 ml of the sodium tripolyphosphate aqueous solution prepared in step (4), and stir and mix them to achieve cross-linking, so as to obtain a nano hydrogel.
[0089] Embodiment 12:
[0090] Preparation method:
[0091] (1) Crush the six medicinal materials of camellia oleifera, Gleditsia sinensis, Sophora flavescens, Flos lonicerae, Phellodendron chinense, and Rhizoma Coptidis respectively, and pass through a 10-mesh sieve to obtain powder;
[0092] (2) Add 10 times the amount of purified water to the oil-tea camellia herb powder, heat to boil, and then simmer for 25 minutes to mature it;
[0093] (3) adding the powders of Chinese sapodilla, sophora flavescens, honeysuckle, phellodendron amurense and coptis chinensis to the tea oil cake matured in step 2), deducting the volume of the tea oil cake water, adding 10 times the amount of purified water and 10% by weight of white sugar to the total amount of the medicinal materials, heating and boiling for sterilization, cooling to room temperature, adding 8% high-efficiency distiller's yeast and fermenting for 5 days, adding 0.5% to 1% of acetobacter and continuing fermentation and extraction for 18 days, inactivating at high temperature, filtering the fermentation liquid, and concentrating the supernatant to 1 / 3 of the original liquid volume to obtain a concentrated liquid;
[0094] (4) taking a certain amount of chitosan and sodium tripolyphosphate, adding chitosan to a 3% acetic acid solution, and adding sodium tripolyphosphate to distilled water, stirring and dissolving them completely to obtain a chitosan acetic acid solution with a concentration of 2 mg / ml and a sodium tripolyphosphate aqueous solution with a concentration of 1.25 mg / ml, respectively;
[0095] (5) Take 25 ml of the concentrated solution prepared in step (3) and add it to the chitosan acetate solution prepared in step (4), then mix the chitosan acetate solution containing the concentrated solution with 10 ml of the sodium tripolyphosphate aqueous solution prepared in step (4), and stir and mix them to achieve cross-linking, so as to obtain a nano hydrogel.
[0096] Embodiment 13:
[0097] Preparation method:
[0098] (1) Crush the six medicinal materials of camellia oleifera, Gleditsia sinensis, Sophora flavescens, Flos lonicerae, Phellodendron chinense, and Rhizoma Coptidis respectively, and pass through a 30-mesh sieve to obtain powder;
[0099] (2) Add 25 times the amount of purified water to the oil-tea camellia herb powder, heat to boil, and then simmer for 35 minutes to mature it;
[0100] (3) adding the powders of Chinese sapodilla, sophora flavescens, honeysuckle, phellodendron chinense and coptis chinensis to the tea oil cake matured in step 2), deducting the volume of the tea oil cake water, adding 20 times the amount of purified water and 20% by weight of white sugar to the total amount of the medicinal materials, heating and boiling for sterilization, cooling to room temperature, adding 10% of high-efficiency distiller's yeast and fermenting for 5 days, adding 0.5% to 1% of acetobacter and continuing fermentation and extraction for 22 days, inactivating at high temperature, filtering the fermentation liquid, and concentrating the supernatant to 1 / 3 of the volume of the original liquid to obtain a concentrated liquid;
[0101] (4) taking a certain amount of chitosan and sodium tripolyphosphate, adding chitosan to a 4% acetic acid solution, and adding sodium tripolyphosphate to distilled water, stirring and dissolving them completely to obtain a chitosan acetic acid solution with a concentration of 2 mg / ml and a sodium tripolyphosphate aqueous solution with a concentration of 1.25 mg / ml, respectively;
[0102] (5) Take 25 ml of the concentrated solution prepared in step (3) and add it to the chitosan acetate solution prepared in step (4), then mix the chitosan acetate solution containing the concentrated solution with 10 ml of the sodium tripolyphosphate aqueous solution prepared in step (4), and stir and mix them to achieve cross-linking, so as to obtain a nano hydrogel.
[0103] Embodiment 14:
[0104] Preparation method:
[0105] (1) Crush the six medicinal materials of camellia oleifera, Gleditsia sinensis, Sophora flavescens, Flos lonicerae, Phellodendron chinense, and Rhizoma Coptidis respectively, and pass through a 20-mesh sieve to obtain powder;
[0106] (2) Add 20 times the amount of purified water to the oil-tea camellia oleifera powder, heat to boil, and then simmer for 30 minutes to mature it;
[0107] (3) adding the powders of Chinese sapodilla, sophora flavescens, honeysuckle, phellodendron amurense and coptis chinensis to the matured camellia oleifera seed cake in step 2), deducting the volume of the water content of the camellia oleifera seed cake, adding 15 times the amount of purified water and 15% by weight of white sugar to the total amount of the camellia oleifera seed cake, heating and boiling for sterilization, cooling to room temperature, adding 9% high-efficiency distiller's yeast for fermentation and extraction for 20 days, inactivating the mixture at high temperature, filtering the fermentation liquid, and concentrating the supernatant to 1 / 3 of the volume of the original liquid to obtain a concentrated liquid;
[0108] (4) Add polyoxyethylene stearyl alcohol ether to the concentrate to prepare a water-in-oil emulsifier, add a stabilizer, filter and sterilize the concentrate, and then put it into a spray bottle.
[0109] Embodiment 15:
[0110] Preparation method:
[0111] (1) Crush the six medicinal materials of camellia oleifera, Gleditsia sinensis, Sophora flavescens, Flos lonicerae, Phellodendron chinense, and Rhizoma Coptidis respectively, and pass through a 20-mesh sieve to obtain powder;
[0112] (2) Add 20 times the amount of purified water to the oil-tea camellia oleifera powder, heat to boil, and then simmer for 30 minutes to mature it;
[0113] (3) adding the powders of Chinese sapodilla, sophora flavescens, honeysuckle, phellodendron amurense and coptis chinensis to the oil tea dregs matured in step 2), deducting the volume of the water content of the oil tea dregs, adding 15 times the amount of purified water of the total amount of the medicinal materials and 15% by weight of white sugar of the total amount of the medicinal materials, heating and boiling for sterilization, cooling to room temperature, adding 9% of high-efficiency distiller's yeast and fermenting for 6 days, adding 0.5% to 1% of acetobacter and continuing to ferment and extract for 20 days, inactivating at high temperature, filtering the fermentation liquid, and concentrating the supernatant to 1 / 3 of the volume of the original liquid to obtain a concentrated liquid;
[0114] (4) Add polyoxyethylene stearyl alcohol ether to the concentrate to prepare a water-in-oil emulsifier, add a stabilizer, filter and sterilize the concentrate, and then put it into a spray bottle.
[0115] Experimental example:
[0116] The inventors have conducted a large number of experimental studies on the formulation, preparation process and effectiveness of the present invention, some of which are excerpted as follows:
[0117] 1. Formula source and screening test
[0118] In order to solve the problems of the existing eczema treatment drugs, such as the large variety of raw materials, the single clinical drug treatment range, easy recurrence after treatment, and poor treatment effect, the inventors screened 17 kinds of medicinal materials such as honeysuckle, sapodilla, camellia oleifera, sophora flavescens, dandelion, and coix seed for mouse eczema model by consulting literature and investigating the drug use habits of ethnic minorities, and scored them according to the apparent observation and the frequency of itching and scratching of mice, and scored the total skin lesion score on the day the treatment ended.
[0119] The scoring criteria were as follows: (1) Erythema: no erythema was scored as 0 point, mild erythema was scored as 1 point, obvious erythema without crust was scored as 2 points, moderate erythema with mild to moderate crust was scored as 3 points, and severe erythema with severe crust was scored as 4 points; (2) Edema: no edema was scored as 0 point, mild edema was scored as 1 point, moderate edema was scored as 2 points, and severe edema was scored as 3 points; (3) Scratches: no scratches were scored as 0 point, and scratches were scored as 1 point.
[0120] The total score is the cumulative sum of the above scores, and the results are shown in Table 1.
[0121] Table 1: Apparent characteristic scores of 17 medicinal materials in treating eczema C57 mice (n=10)
[0122]
[0123]
[0124] Compared with the model group, * indicates P < 0.05, ** indicates P < 0.01.
[0125] According to the results of the contribution scores of the medicinal materials, combined with the effective components of the medicinal materials, the prescriptions were formulated according to the principles of Chinese medicine compatibility. Four prescriptions were selected according to the effectiveness of the medicinal materials: Gleditsia sinensis, camellia oleifera, Sophora flavescens, honeysuckle, Phellodendron chinense, Coptis chinensis, Taraxacum officinale, and Imperata cylindrica.
[0126] Formula 1: Gleditsia sinensis 15, Sophora flavescens 15, Taraxacum officinale 10, Imperata cylindrica 8, Coptis chinensis 6, Phellodendron amurense 4;
[0127] Formula 2: Camellia oleifera 15, Sophora flavescens 15, Taraxacum officinale 10, Honeysuckle 8, Coptis chinensis 6, Phellodendron amurense 4;
[0128] Formula 3: Camellia oleifera 15, Gleditsia sinensis 15, Sophora flavescens 10, Honeysuckle 8, Phellodendron amurense 6, Coptis chinensis 4;
[0129] Formula 4: 15 grams of camellia oleifera seed, 15 grams of sapodilla, 10 grams of dandelion, 8 grams of Imperata root, 6 grams of Coptis chinensis, and 4 grams of Phellodendron amurense.
[0130] The four formulas were fermented and then screened in mouse eczema model. The results are shown in Table 2.
[0131] Table 2: Effects of different herbal prescriptions on the apparent scores of eczema mice (n=10)
[0132]
[0133]
[0134] Compared with the model group, * indicates P < 0.05, ** indicates P < 0.01.
[0135] After experimental screening, according to the test scores, the present invention selects formulation three as the best formulation, that is, the compatibility of medicinal materials in the present invention: the compatibility combination of camellia oleifera, sapodilla fruit, honeysuckle, sophora flavescens, phellodendron amurense, and coptis chinensis.
[0136] 2. Principles of formula selection
[0137] Eczema (eczema) is a common dermatological disease, characterized by polymorphic lesions, symmetrical distribution, exudative tendency, conscious itching, and recurrent attacks. In particular, chronic eczema has an uncertain course, which brings long-term chronic pain and economic pressure to patients. Traditional Chinese medicine plays a positive role in the treatment of eczema with its holistic concept and syndrome differentiation and treatment characteristics.
[0138] Eczema belongs to the category of "wet sores", "immersion sores" and "hydrangea wind" in traditional Chinese medicine. For example, "The Treatise on the Causes and Symptoms of Various Diseases·Wet Tinea Symptoms" says: "Wet tinea is like insects crawling, soaking, and itching. Scratching it will cause ulcers. It is because the wind and poison are shallow, and there is more dampness and less wind, so it is wet tinea." This shows that eczema is caused by a variety of internal and external factors. Wind, dampness and heat are the main pathogenic evils. Over time, they are transmitted into the body, and the lesions on the surface of the skin affect the internal organs, damaging the lungs, spleen, heart, liver and kidneys. It is closely related to qi, blood, meridians and internal organs. Modern doctors believe that eczema often occurs on the basis of intolerance, and is affected by external evils such as wind, dampness, dryness and fire, or the spleen fails to function properly, and the water stagnates and accumulates in the skin to cause eczema, or the yin and yang of the internal organs are too strong or too weak. If the yin is too strong, it is negative eczema, and if the yang is too strong, it becomes positive eczema.
[0139] The inventors of the present invention have made a purposeful selection based on the efficacy of traditional Chinese medicine itself and the accurate syndrome differentiation, combined with the pathological mechanism of eczema, with the aim of nourishing blood and extinguishing wind, clearing away heat and detoxifying, combined with the principles of traditional Chinese medicine compatibility. Modern Chinese medicine pharmacology research shows that the effective ingredients of oil tea ash have good effects in antibacterial, anti-inflammatory, heat-clearing and detoxifying aspects; oil tea ash contains a large amount of effective ingredients such as tea saponins, flavonoids, polysaccharides, among which flavonoids have the functions of anti-inflammatory and detumescence, insecticidal and antipruritic, and immune enhancement. Tea oil is also used as a treatment for eczema by the people, and the effect of oil tea ash fermentation liquid in treating eczema is better after activity screening, so it is used in combination with large saponin as the main drug in the present invention; large saponin has the effects of sterilization, dehumidification and "dispersing wind and qi", contains saponins, flavonoids, alkaloids, tannic acid, polyphenols and other chemical components, saponins have the effects of insecticidal, sterilization and antipruritic, and are also used in the treatment of scrotal eczema by the people. Combined with the activity screening experimental data, large saponin has a good therapeutic effect on eczema mice, so it is used in combination with oil tea ash as the main drug to play a synergistic effect; Heat-clearing and dampness-removing, antibacterial and anti-inflammatory, insecticidal and antipruritic, mostly containing alkaloids and flavonoids, its alkaloids have a good curative effect on sterilization and antipruritic, and also have a good therapeutic effect on eczema. Combined with the efficacy test, it is used as a finished medicine in the present invention to play a synergistic effect; honeysuckle mainly clears heat and detoxifies, anti-inflammatory, tonifying and treating wind, mainly contains alkaloids, flavonoids, gallic acid and other ingredients, the therapeutic effect of flavonoids and organic acids on eczema has been documented, combined with the activity screening data, it is used as a guide drug in this prescription to synergistically exert the efficacy; Phellodendron chinense clears heat and detoxifies, dries dampness and purges fire, the main drug contains alkaloids, phellodendron lactone, phellodendron ketone and other effective ingredients, its alkaloids are reported in the literature to have a strong therapeutic effect on drug-induced eczema and ear-face eczema, and it is often used in combination with Coptis chinensis to treat eczema, which plays a role in removing dampness and heat. Combined with the activity screening results, it is used as a guide drug together with Coptis chinensis. Coptis chinensis clears heat and dries dampness, purges fire and detoxifies, and is used as a guide drug together with Phellodendron chinense.
[0140] The above Chinese herbal medicines contain relatively rich triterpenes and triterpenoid saponins, flavonoids, tannins, alkaloids and other substances, and have the characteristics of multiple targets and multiple effects in the treatment of eczema. The prescription of the present invention is in accordance with the compatibility principle of Chinese medicine, combining movement and stillness, dispersing and astringing, combining yin and yang, regulating qi and blood, and assisting the liver. The whole prescription combination has the functions of clearing away heat and detoxicating, calming the liver and extinguishing wind. That is, the prescription is: 15 parts of oil tea dregs, 15 parts of large saponins, 10 parts of sophora flavescens, 8 parts of honeysuckle, 6 parts of phellodendron, and 4 parts of coptis.
[0141] 3. Process optimization test
[0142] The present invention compares the therapeutic effects of a decoction of a drug combination with those of a fermentation liquid with or without Acetobacter on C57 mice with eczema, and evaluates the therapeutic effects of the three preparations on mice with eczema based on the apparent scores. The experimental results show that the therapeutic effect of the formula after fermentation is significantly better than that of the decoction, and there is a statistically significant difference (P<0.05 or P<0.01), indicating that the formula prepared by the fermentation process has a more significant therapeutic effect.
[0143] Table 1: Comparison of the efficacy of the drug combination of the present invention before and after fermentation
[0144] Group Number of mice Back skin surface score Model Group 10 6.01±0.34△ Positive control group 10 2.24±0.63**△ Decoction group 10 4.17±0.21* Fermentation broth without acetic acid 10 2.31±0.44**△ Acetobacter fermentation broth 10 2.29±0.27**△
[0145] Compared with the model group, * indicates P < 0.05, ** indicates P < 0.01. Compared with the decoction group, △ indicates P < 0.05, △△ indicates P < 0.01.
[0146] During the activity screening process, the efficacy of each medicinal material in this prescription is compared before and after fermentation. Due to the different components and properties of Chinese medicinal materials, the present invention selects medicinal materials with enhanced efficacy after fermentation as the compatibility composition, and also compares the efficacy of the optimal formula screened out before and after fermentation to determine the experimental process, so as to achieve better therapeutic effects.
[0147] 4. Pharmacodynamics research
[0148] 4.1 Animal experiments
[0149] 4.1.1 Experimental plan
[0150] (1) Animal modeling
[0151] The delayed-type hypersensitivity reaction of C57BL / 6 mice (referred to as C57 in the present invention) was induced by 2,4-dinitrochlorobenzene (DNCB), thereby creating a chronic dermatitis-eczema model in mice.
[0152] Specifically: 70 male C57 mice, 4-6 weeks old, were randomly selected. After one week of adaptive feeding, except for 10 mice in the blank group, 2*2cm of the abdomen of the remaining mice in each group was shaved, and then 100μL of 7% DNCB-acetone solution was applied to the abdomen of the mice for 3 consecutive days.
[0153] (2) Grouping and drug administration
[0154] The mice after modeling were divided into a model group, a positive control 999 dermatitis flat group, a group without acetobacillus fermentation broth of the present invention, and low, medium and high dose groups of acetobacillus fermentation broth of the present invention according to body weight, with 10 mice in each group. On the 5th day after modeling, 3*3cm of the back of the mice were shaved, 10μL of 1% DNCB-acetone solution was applied to the auricles of both sides of the mice, and 100μL was applied to the back every 4 days for sensitization. After the 5th day of modeling, the corresponding drug solution was given to each group of mice according to the grouping, and the sensitized part of the back of the mice was applied. The drug was administered continuously for 28 days, and 10μL of 1% DNCB-acetone solution was applied to the right ear of the mice on the last day.
[0155] (3) Detection indicators
[0156] Carry out corresponding tests according to the following indicators.
[0157] Record of apparent healing of mice: On the day when the experiment ended, the skin healing of each group of mice was observed and scored, and photos were taken to verify the healing effect of the present invention on eczema in C57 mice.
[0158] Effect of drugs on ear swelling in mice: After the experiment, the mice were killed, the ear pieces on both sides of the mice were cut off, and a metal punch with a diameter of 0.8 cm was used to punch holes at the same position in the middle of the left and right ears to obtain round ear pieces. They were immediately weighed with a 1 / 10,000 balance, and the ear swelling was calculated. The swelling degree (mg) = the mass of the right ear piece (mg) - the mass of the left ear piece (mg), and the swelling inhibition rate was calculated. The ear swelling inhibition rate (%) = (the ear swelling degree of the model group - the ear swelling degree of the drug-treated group) / the ear swelling degree of the model group × 100%.
[0159] Changes in the content of immune factors in mouse serum: The EILSA kit was used to measure the content of cytokines such as IgE, helper CD4+T cells (CD4+), IL-4, IL-17, etc. in the serum of the mouse canthus vein serum, and the effect of the present invention on the content of immunoglobulin E (IgE), interleukin 4 (IL-4), interleukin 17 (IL-17), and helper CD4+T cells in the serum of C57 mice with eczema was investigated.
[0160] HE staining observation of mouse affected area tissue sections: After the experiment, the skin of the modeling area on the back of the mouse was taken for HE case sections.
[0161] (4) Scoring criteria
[0162] On the day when the treatment was completed, the skin lesions of the mice were scored according to the scoring criteria.
[0163] Scoring indicators are: erythema: no erythema is 0 points, mild erythema is 1 point, obvious erythema without crust is 2 points, moderate erythema with mild to moderate crust is 3 points, severe erythema with severe crust is 4 points; edema: no edema is 0 points, mild edema is 1 point, moderate edema is 2 points, severe edema is 3 points; scratches: no scratches are 0 points, scratches are 1 point. The total score is the cumulative sum of the above scores.
[0164] 4.1.2 Experimental results and analysis
[0165] (1) Observation results of the therapeutic effect of the pharmaceutical composition of the present invention on the healing status of eczema mice
[0166] The results of the observation and scoring of the apparent healing status of the therapeutic effect of the pharmaceutical composition of the present invention on eczema mice are shown in Tables 2 and Figure 1 .
[0167] Table 2: The present invention on the apparent characteristic scores of eczema C57 mice (n = 10)
[0168] Group Number Back skin surface score Blank group 10 ------ Model Group 9 6.16±0.87 Positive control group 7 3.53±0.36** Group without Acetobacter 8 2.03±0.41** Acetobacter low dose group 7 4.16±0.23** Acetobacter medium dose group 9 2.23±0.32** Acetobacter high dose group 8 2.01±0.15**
[0169] Compared with the model group, * indicates P < 0.05, ** indicates P < 0.01
[0170] Test conclusion: As shown in Figure A and Table 2, the present invention has a good curative effect on chronic eczema in mice caused by BNCB. Compared with the model group, the epidermis of mice in the model group was thickened, with erythema, scabs, and scratches, and the epidermis was not smooth; the epidermis of mice in the positive control group had no scratches or erythema, and the epidermis was smooth, but the epidermis was thickened and had scabs, and the hair grew slowly; the eczema C57 mice were basically cured after 28 days of treatment without adding acetobacter fermentation liquid. The skin on the affected part of the back of the mice had no scabs, no thickening of the epidermis, and the epidermis was smooth without hair growth, without redness, swelling, or scratches, and a large amount of hair had grown. The mice in the low-dose group with acetobacter fermentation liquid had a small amount of erythema and scratches, no thickening of the epidermis, no scabs, and some hair had grown; the mice in the medium and high-dose groups had a small amount of erythema, no thickening of the epidermis, no scratches, smooth epidermis, no scratches, and a large amount of hair had grown. From the scores in Table 2, it can be concluded that compared with the model group, the mice in each drug-treated group recovered better, and the difference was extremely significant (P<0.01).
[0171] (2) Observation results of the drug composition of the present invention on the treatment of ear swelling in mice with eczema
[0172] The observation and scoring results of the effect of the pharmaceutical composition of the present invention on the swelling of the auricles of mice with eczema are shown in Table 3.
[0173] Table 3: Inhibitory effect of the present invention on ear swelling in C57 mice with eczema
[0174] Group Ear swelling Auricular swelling inhibition rate % Blank group ----- ------ Model Group 6.41±0.66 - Positive control group 1.89±0.45** 70.51 Group without Acetobacter 2.34±0.68** 63.49 Acetobacter low dose group 4.91±0.57 23.40 Acetobacter medium dose group 3.29±0.32** 48.67 Acetobacter high dose group 2.21±0.14** 65.52
[0175] Compared with the model group, * indicates P < 0.05, ** indicates P < 0.01;
[0176] Test conclusion: The results in Table 2 show that compared with the blank group, the difference in thickness between the left and right ears of the model group mice after stimulation, that is, the swelling, increased significantly (P<0.01). Compared with the model group, the swelling of the right ear of the 999 Piyanping group and the groups of mice in the present invention decreased to varying degrees. Except for the group of mice in the present invention adding low-concentration acetobacter fermentation liquid, the differences in the other groups were statistically significant (P<0.05 or P<0.01).
[0177] (3) Effect of the pharmaceutical composition of the present invention on immune factors in the serum of C57 eczema mice
[0178] The effects of the pharmaceutical composition of the present invention on the immune factors in the serum of C57 eczema mice are shown in Table 4.
[0179] Table 4: Effects of the present invention on immune factors in the serum of C57 mice with eczema (n=10)
[0180]
[0181]
[0182] Compared with the blank group, # indicates P < 0.05, ## indicates P < 0.01; compared with the model group, * indicates P < 0.05, ** indicates P < 0.01;
[0183] Experimental conclusion: The results in Table 4 show that after DNCB modeling, the immunoglobulin IgE content in the serum increased. Compared with the blank group, the IgE content in the model group increased significantly (P<0.01), indicating that the model was successfully established. After drug treatment, the IgE content in the serum decreased. Compared with the model group, the IgE content of mice in each drug-treated group was significantly reduced (P<0.05 or P<0.01), among which the IgE content in the serum of the positive control group and the group without acetic acid fermentation broth was restored to normal levels; after modeling, the CD4+ content of immune cells in the serum of mice decreased. Compared with the blank group, the CD4+ content in the serum of mice in the model group decreased significantly, and the difference was extremely significant (P<0.01), indicating that modeling, when given After drug treatment, the CD4+ content in the serum of mice increased. After the drug administration, the CD4+ content of mice in each group was significantly different from that in the model group (P<0.05 or P<0.01), and the positive control group and the group without acetobacter fermentation broth and the high-dose group of acetobacter fermentation broth increased to normal levels (P<0.01); after modeling, interleukins IL-4 and IL-17 increased significantly. Compared with the blank group, the content of the model group increased extremely significantly. After drug administration, the IL-4 and IL-17 contents of mice in each drug administration group decreased. Compared with the model group, the difference was significant (P<0.05 or P<0.01), and the positive control group and the group without acetobacter fermentation broth and the high-dose group of acetobacter fermentation broth almost recovered to normal levels. This indicates that this medicine can promote the proliferation of immunoglobulin IgE and immune cells CD4+ in the serum of C57 mice with eczema, and has a down-regulating effect on interleukins IL-4 and IL-17, and has a certain therapeutic effect on C57 mice with eczema.
[0184] (4) Observation of HE staining of mouse affected tissue sections by the pharmaceutical composition of the present invention
[0185] HE staining of mouse affected tissue sections by the pharmaceutical composition of the present invention is shown in Figure 2 .
[0186] Test conclusion: Figure 2 The results show that the epidermal structure of the skin in the normal group is intact, and the dermis fibers are neatly arranged. Compared with the model group, the epidermis of the mice in the model group is thickened, and the epidermis protrudes downward; the stratum corneum is found to be incompletely keratinized and hyperkeratinized, and the dermis is infiltrated with inflammatory cells; the tissue is mildly edematous, and the stratum corneum, stratum spinosum, and stratum granulosum are obviously hypertrophic. Compared with the model group, the stratum spinosum hyperplasia of the medium and high dose groups of the acetic acid fermentation liquid of the present invention and the fermentation liquid group without acetic acid is less than that of the model group, and the superficial dermis fibrous connective tissue is slightly hyperplastic, and no inflammatory cell infiltration is observed, and the skin structure tends to be normal. It can be seen that the group of the present invention can improve the symptoms of eczema in C57 mice with eczema.
[0187] 4.2 Antibacterial effect experiment of fermentation broth
[0188] (1) Experimental plan
[0189] The selected revived Staphylococcus aureus and Escherichia coli strains were cultured on NA medium and divided into 4 areas for drug administration, among which 1 in the figure represents a medium dose of Acetobacter, 2 represents a high dose, 3 represents no addition of Acetobacter fermentation broth, and positive represents the positive control drug penicillin.
[0190] (2) Experimental conclusion
[0191] The antibacterial properties of the fermentation broth prepared by the present invention are shown in Figure 3 .
[0192] from Figure 3 Results The experimental results show that the high-dose group of the present invention has antibacterial activity against Escherichia coli and Staphylococcus aureus, and the two fermentation broths of the present invention have a certain antibacterial effect on Staphylococcus aureus.
[0193] Although the present invention has been described in detail above by means of general description, specific implementation methods and experiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.
Claims
1. A pharmaceutical composition for treating eczema, characterized in that: The medicine composition is prepared from the following raw materials in parts by weight: 10-20 parts of camellia oleifera seed, 10-20 parts of sapodilla fruit, 6-15 parts of sophora flavescens, 5-12 parts of honeysuckle, 3-10 parts of phellodendron amurense and 1-7 parts of coptis root.
2. A pharmaceutical composition for treating eczema according to claim 1, characterized in that: The medicine composition is prepared from the following raw materials in parts by weight: 14-16 parts of camellia oleifera seed, 14-16 parts of sapodilla fruit, 8-12 parts of sophora flavescens, 7-9 parts of honeysuckle, 5-7 parts of phellodendron amurense and 3-5 parts of coptis root.
3. A pharmaceutical composition for treating eczema according to claim 2, characterized in that: The medicine composition is prepared from the following raw materials in parts by weight: 15 parts of camellia oleifera seed, 15 parts of sapodilla fruit, 10 parts of sophora flavescens, 8 parts of honeysuckle, 6 parts of phellodendron amurense and 4 parts of coptis root.
4. A method for preparing the pharmaceutical composition according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: 1) Crush the six medicinal materials of camellia oleifera, Gleditsia sinensis, Sophora flavescens, Flos Lonicerae, Phellodendron chinense, and Rhizoma Coptidis respectively, and pass through a 10-30 mesh sieve to obtain powder; 2) Add 10 to 25 times the amount of purified water to the oil-tea camellia oleifera powder, heat to boil, and then simmer for 25 to 35 minutes to mature it; 3) adding the powders of Chinese sapodilla, sophora flavescens, honeysuckle, phellodendron and coptis chinensis to the stale camellia oleifera seed after being matured in step 2), deducting the volume of the water content of the camellia oleifera seed, adding 10 to 20 times the amount of purified water and 10% to 20% by weight of white sugar of the total amount of the camellia oleifera seed, heating and boiling for sterilization, cooling to room temperature, adding 8 to 10% of high-efficiency distiller's yeast for fermentation and extraction for 18 to 22 days, inactivating at high temperature, filtering the fermented liquid, and concentrating the supernatant to 1 / 3 of the volume of the original liquid to obtain a concentrated liquid; 4) Adding pharmaceutically acceptable excipients to the concentrated solution to prepare a pharmaceutically acceptable preparation.
5. The preparation method according to claim 4, characterized in that: The method comprises the following steps: A1: Crush the six medicinal materials of camellia oleifera, Gleditsia sinensis, Sophora flavescens, Flos lonicerae, Phellodendron chinense, and Rhizoma Coptidis respectively, and pass through a 20-mesh sieve to obtain powder; A2: Add 20 times the amount of purified water to the oil-tea camellia herb powder, heat to boil, and then simmer for 30 minutes to mature it; A3: Add the powder of Chinese ginseng, sophora flavescens, honeysuckle, phellodendron and coptis chinensis to the matured camellia oleifera dregs in step 2), deduct the volume of the water content of the camellia oleifera dregs, add 15 times the amount of purified water and 15% by weight of white sugar to the total amount of the medicinal materials, heat and boil to sterilize, cool to room temperature, add 9% high-efficiency distiller's yeast and ferment for 20 days, inactivate at high temperature, filter the fermentation liquid, take the supernatant and concentrate to 1 / 3 of the volume of the original liquid to obtain a concentrated liquid; A4: Add pharmaceutically acceptable excipients to the concentrated solution to prepare a pharmaceutically acceptable preparation.
6. The preparation method according to claim 4 or 5, characterized in that: In step 3), after adding high-efficiency distiller's yeast and fermenting for 5 to 6 days, 0.5% to 1% of acetic acid bacteria can be added to continue fermentation.
7. The preparation method according to any one of claims 4 to 6, characterized in that: The preparation is a semisolid preparation or a liquid preparation.
8. The preparation method according to claim 7, characterized in that: The semisolid preparation is an ointment, and the liquid preparation is a nano-microemulsion, a liniment, a gel, an aerosol, or a spray.
9. The preparation method according to claim 8, characterized in that: The gelling agent is a nano hydrogel, and the preparation method of the nano hydrogel is specifically as follows: B1: Take a certain amount of chitosan and sodium tripolyphosphate, add chitosan into 2% to 4% acetic acid solution, add sodium tripolyphosphate into distilled water, stir and dissolve completely, and obtain chitosan acetic acid solution and sodium tripolyphosphate aqueous solution respectively; B2: Take 25 ml of the concentrated solution prepared in step A3 and add it to the chitosan acetate solution prepared in step B1. Then mix the chitosan acetate solution containing the concentrated solution with 10 ml of the sodium tripolyphosphate aqueous solution prepared in step B1, and stir and mix them evenly to cross-link them to obtain the nano hydrogel.
10. Use of the pharmaceutical composition according to any one of claims 1 to 3 in the preparation of a drug for treating acute, chronic and pediatric eczema caused by the environment, pathogens and immune disorders.
